Financhill
Sell
49

PBYI Quote, Financials, Valuation and Earnings

Last price:
$3.32
Seasonality move :
-5.1%
Day range:
$3.29 - $3.46
52-week range:
$2.23 - $6.06
Dividend yield:
0%
P/E ratio:
5.44x
P/S ratio:
0.70x
P/B ratio:
1.79x
Volume:
265.7K
Avg. volume:
425.6K
1-year change:
-36.4%
Market cap:
$164.7M
Revenue:
$230.5M
EPS (TTM):
$0.61

Analysts' Opinion

  • Consensus Rating
    Puma Biotechnology has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $4.33, Puma Biotechnology has an estimated upside of 30.52% from its current price of $3.32.
  • Price Target Downside
    According to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $3.32.

Fair Value

  • According to the consensus of 1 analyst, Puma Biotechnology has 30.52% upside to fair value with a price target of $4.33 per share.

PBYI vs. S&P 500

  • Over the past 5 trading days, Puma Biotechnology has underperformed the S&P 500 by -1.15% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Puma Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Puma Biotechnology revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Puma Biotechnology reported revenues of $59.1M.

Earnings Growth

  • Puma Biotechnology has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Puma Biotechnology reported earnings per share of $0.39.
Enterprise value:
130.8M
EV / Invested capital:
0.82x
Price / LTM sales:
0.70x
EV / EBIT:
3.58x
EV / Revenue:
0.57x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
3.37x
Price / Operating cash flow:
4.16x
Enterprise value / EBITDA:
2.72x
Gross Profit (TTM):
$166.1M
Return On Assets:
13.97%
Net Income Margin (TTM):
13.14%
Return On Equity:
47.89%
Return On Invested Capital:
20.19%
Operating Margin:
22.62%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $228M $235.6M $230.5M $72.2M $59.1M
Gross Profit $172.9M $173M $166.1M $47.9M $45.2M
Operating Income $30.7M $33.3M $31M $14.8M $13.4M
EBITDA $21.9M $47.5M $48.1M $19M $17.7M
Diluted EPS -- $0.45 $0.61 $0.25 $0.39
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $146.1M $140M $134.3M $156.2M $147.7M
Total Assets $244.2M $226.6M $222.1M $230.5M $213.3M
Current Liabilities $114.3M $109.6M $77.5M $99.4M $96.1M
Total Liabilities $250.2M $229M $200.5M $177.1M $121.2M
Total Equity -$6M -$2.4M $21.6M $53.4M $92.1M
Total Debt $98.3M $97.1M $98.3M $99.7M $67M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$15.8M $27M $38.9M $10.5M $15.6M
Cash From Investing $7.1M -$19.1M -$20.4M -$8.2M -$2.3M
Cash From Financing $12.2M -- -$33.8M -- -$11.3M
Free Cash Flow -$15.8M $14.4M $38.9M $10.4M $15.6M
PBYI
Sector
Market Cap
$164.7M
$38.4M
Price % of 52-Week High
54.83%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
-36.4%
-39.05%
Beta (5-Year)
1.334
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $3.45
200-day SMA
Buy
Level $3.07
Bollinger Bands (100)
Buy
Level 2.79 - 3.25
Chaikin Money Flow
Sell
Level -36.8M
20-day SMA
Buy
Level $3.17
Relative Strength Index (RSI14)
Buy
Level 54.16
ADX Line
Buy
Level 25.73
Williams %R
Neutral
Level -41.3462
50-day SMA
Buy
Level $3.09
MACD (12, 26)
Buy
Level 0.13
25-day Aroon Oscillator
Buy
Level 64
On Balance Volume
Sell
Level -26.6M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-5.9519)
Buy
CA Score (Annual)
Level (-0.1046)
Buy
Beneish M-Score (Annual)
Level (-2.9052)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.3985)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Stock Forecast FAQ

In the current month, PBYI has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PBYI average analyst price target in the past 3 months is $4.33.

  • Where Will Puma Biotechnology Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Puma Biotechnology share price will rise to $4.33 per share over the next 12 months.

  • What Do Analysts Say About Puma Biotechnology?

    Analysts are divided on their view about Puma Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Puma Biotechnology is a Sell and believe this share price will drop from its current level to $2.00.

  • What Is Puma Biotechnology's Price Target?

    The price target for Puma Biotechnology over the next 1-year time period is forecast to be $4.33 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is PBYI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Puma Biotechnology is a Hold. 1 of 1 analysts rates the stock a Hold at this time.

  • How Can I Buy Shares Of PBYI?

    You can purchase shares of Puma Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Puma Biotechnology shares.

  • What Is The Puma Biotechnology Share Price Today?

    Puma Biotechnology was last trading at $3.32 per share. This represents the most recent stock quote for Puma Biotechnology. Yesterday, Puma Biotechnology closed at $3.32 per share.

  • How To Buy Puma Biotechnology Stock Online?

    In order to purchase Puma Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

Sell
50
NUTX alert for Mar 15

Nutex Health [NUTX] is up 14.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock